Zealand Pharma A/S (ZEAL.CO)
DKK 485.7
(4.12%)
DKK 485.7
(4.12%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -249.03 Million DKK | 60.2% |
| 2022 | -625.76 Million DKK | -83.15% |
| 2021 | -341.67 Million DKK | 53.89% |
| 2020 | -740.92 Million DKK | 25.56% |
| 2019 | -995.3 Million DKK | -15.65% |
| 2018 | -860.63 Million DKK | -89.99% |
| 2017 | -452.98 Million DKK | -5182.28% |
| 2016 | 8.91 Million DKK | 108.42% |
| 2015 | -105.84 Million DKK | 60.22% |
| 2014 | -266.1 Million DKK | 7.01% |
| 2013 | -286.17 Million DKK | 20.27% |
| 2012 | -358.92 Million DKK | -28.95% |
| 2011 | -278.34 Million DKK | 27.38% |
| 2010 | -383.3 Million DKK | -165.05% |
| 2009 | -144.61 Million DKK | 31.03% |
| 2008 | -209.68 Million DKK | 12.7% |
| 2007 | -240.18 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.76 Billion DKK | -2288.79% |
| 2024 Q1 | -283.21 Million DKK | 14.2% |
| 2023 FY | -249.03 Million DKK | 60.2% |
| 2023 Q2 | -210.82 Million DKK | 33.81% |
| 2023 Q3 | -268.38 Million DKK | -27.3% |
| 2023 Q4 | -330.08 Million DKK | -22.99% |
| 2023 Q1 | -318.52 Million DKK | 49.1% |
| 2022 Q1 | -333.03 Million DKK | 2.53% |
| 2022 Q4 | -625.76 Million DKK | -508.63% |
| 2022 Q2 | -67.81 Million DKK | 79.64% |
| 2022 Q3 | 153.13 Million DKK | 325.8% |
| 2022 FY | -625.76 Million DKK | -83.15% |
| 2021 Q2 | -844 Million DKK | 28.4% |
| 2021 Q3 | -611.56 Million DKK | 27.54% |
| 2021 Q1 | -1.17 Billion DKK | -59.1% |
| 2021 Q4 | -341.67 Million DKK | 44.13% |
| 2021 FY | -341.67 Million DKK | 53.89% |
| 2020 Q3 | -1.09 Billion DKK | 9.55% |
| 2020 Q1 | -898.5 Million DKK | 9.73% |
| 2020 Q2 | -1.21 Billion DKK | -35.13% |
| 2020 FY | -740.92 Million DKK | 25.56% |
| 2020 Q4 | -740.92 Million DKK | 32.53% |
| 2019 Q2 | -837.46 Million DKK | 12.49% |
| 2019 FY | -995.3 Million DKK | -15.65% |
| 2019 Q1 | -956.97 Million DKK | -11.19% |
| 2019 Q3 | -1.17 Billion DKK | -40.23% |
| 2019 Q4 | -995.3 Million DKK | 15.25% |
| 2018 Q4 | -860.63 Million DKK | 41.79% |
| 2018 Q3 | -1.47 Billion DKK | -507.02% |
| 2018 Q2 | -243.58 Million DKK | 31.01% |
| 2018 Q1 | -353.05 Million DKK | 22.06% |
| 2018 FY | -860.63 Million DKK | -89.99% |
| 2017 FY | -452.98 Million DKK | -5182.28% |
| 2017 Q1 | -248.77 Million DKK | -2891.19% |
| 2017 Q3 | -632.75 Million DKK | -305.45% |
| 2017 Q4 | -452.98 Million DKK | 28.41% |
| 2017 Q2 | -156.06 Million DKK | 37.27% |
| 2016 Q2 | 21.85 Million DKK | 138.45% |
| 2016 FY | 8.91 Million DKK | 108.42% |
| 2016 Q1 | -56.83 Million DKK | 46.31% |
| 2016 Q4 | 8.91 Million DKK | -89.81% |
| 2016 Q3 | 87.5 Million DKK | 300.43% |
| 2015 Q3 | -120.65 Million DKK | 27.96% |
| 2015 Q4 | -105.84 Million DKK | 12.28% |
| 2015 FY | -105.84 Million DKK | 60.22% |
| 2015 Q1 | -215.29 Million DKK | 19.09% |
| 2015 Q2 | -167.49 Million DKK | 22.2% |
| 2014 Q2 | -297.62 Million DKK | 14.88% |
| 2014 Q4 | -266.1 Million DKK | 12.41% |
| 2014 Q3 | -303.81 Million DKK | -2.08% |
| 2014 FY | -266.1 Million DKK | 7.01% |
| 2014 Q1 | -349.64 Million DKK | -22.18% |
| 2013 FY | -286.17 Million DKK | 20.27% |
| 2013 Q2 | -325.55 Million DKK | 10.4% |
| 2013 Q4 | -286.17 Million DKK | 14.03% |
| 2013 Q1 | -363.34 Million DKK | -1.23% |
| 2013 Q3 | -332.88 Million DKK | -2.25% |
| 2012 FY | -358.92 Million DKK | -28.95% |
| 2012 Q3 | -371.67 Million DKK | -14.11% |
| 2012 Q4 | -358.92 Million DKK | 3.43% |
| 2012 Q2 | -325.72 Million DKK | 0.26% |
| 2012 Q1 | -326.57 Million DKK | -17.33% |
| 2011 FY | -278.34 Million DKK | 27.38% |
| 2011 Q3 | -291.83 Million DKK | 1.41% |
| 2011 Q4 | -278.34 Million DKK | 4.62% |
| 2011 Q1 | -240.48 Million DKK | 37.26% |
| 2011 Q2 | -296.02 Million DKK | -23.09% |
| 2010 Q4 | -383.3 Million DKK | 0.0% |
| 2010 FY | -383.3 Million DKK | -165.05% |
| 2009 FY | -144.61 Million DKK | 31.03% |
| 2008 FY | -209.68 Million DKK | 12.7% |
| 2007 FY | -240.18 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 291 Million DKK | 185.579% |
| Bavarian Nordic A/S | -1.33 Billion DKK | 81.303% |
| Genmab A/S | -14.09 Billion DKK | 98.233% |
| Gubra A/S | 18.03 Million DKK | 1480.619% |
| Novo Nordisk A/S | 12.61 Billion DKK | 101.974% |
| Orphazyme A/S | -11.26 Million DKK | -2109.921% |
| Pharma Equity Group A/S | 25.99 Million DKK | 1058.199% |